Clinical stage medical sensor company Lifecare AS (Euronext Growth Oslo:LIFE) said on Thursday that it has received notification from the European Patent Office (EPO) that it will grant for a new patent to Lifecare.

The patent relates to chemistry compositions and method for preparing the composition and use of Lifecare's proprietary fluid composition reactive to glucose. This fluid enables glucose monitoring in Lifecare's miniaturised sensor technology through osmotic pressure, improving sensor lifetime, measurement response asymmetry and measurement sensitivity.

Joacim Holter, CEO of Lifecare, believes this patent will strengthen the company's commercial position in accurate and continuous glucose monitoring for people and pets with diabetes.

Lifecare applied for this patent in 2018, and its granting extends the company's technology protection until 2037.